Basic Amiloride Information

• INN (International Nonproprietary Name): Amiloride.
• Brand Names Available In Canada (English): Amiloride, Apo-Amiloride — 5 mg tablets, bottle of 100 (Apotex, Sandoz, Teva Canada).
• ATC Code: C03DB01.
• Forms & Dosages: Tablets most commonly 5 mg; some markets 10 mg tablets; combination products with thiazide diuretics (e.g., hydrochlorothiazide/amiloride).
• Manufacturers In Canada (English): Apotex, Sandoz, Teva.
• Registration Status In Canada (English): Marketed.
• OTC / Rx Classification: Rx Only (prescription-only medication).

Latest Research Highlights

Patients often ask whether new uses have been found for amiloride, and the recent literature is clear.

Research from 2022–2025 continues to emphasise amiloride’s established role as an ENaC‑blocking, potassium‑sparing diuretic rather than novel indications.

International randomised controlled trial meta‑analyses reaffirm that when combined with thiazides, amiloride reduces thiazide‑induced hypokalaemia versus thiazide alone.

Observational safety studies, including provincial pharmacoepidemiology analyses, repeatedly flag higher hyperkalemia risk when amiloride is co‑prescribed with RAAS inhibitors.

Canadian randomised trial activity is limited, so Health Canada labels and post‑market surveillance remain main domestic evidence sources.

Emerging translational work explores inhaled ENaC blockers for airway disease, but clinical benefit in humans has not been established to date.

Real product identifiers used in studies and formularies include INN — amiloride, ATC C03DB01, and Canadian brands such as Amiloride and Apo‑Amiloride (5 mg tablets, bottles of 100).

Key Study Types:

• Randomised controlled trials comparing combination therapy versus thiazide alone.
• Large observational pharmacoepidemiology cohorts monitoring adverse events.
• Translational early‑phase studies on inhaled ENaC blockers.

Data Highlights For Safety Signals:

• Clinically meaningful hyperkalemia rates rise when amiloride is combined with ACEi/ARB.
• Recommendation translated into more frequent potassium and creatinine checks in older adults and patients on RAAS therapy.

Clinical Effectiveness In Canada

What can patients expect when amiloride is prescribed in Canadian practice?

Health Canada lists amiloride as a marketed prescription product supplied in Canada as Amiloride or Apo‑Amiloride (5 mg tablets, bottles of 100) from Apotex, Sandoz and Teva.

Effectiveness in Canada mirrors international guidance: amiloride is effective for oedema and as adjunctive therapy for hypertension, particularly to reduce thiazide‑related potassium loss.

Canadian clinical monographs prioritise renal function and potassium monitoring and Health Canada safety communications underline elevated risks in renal impairment.

Formulary coverage varies by province; Ontario Drug Benefit, BC PharmaCare and RAMQ may list generic amiloride or thiazide‑combination products differently, so check online formularies for DIN‑specific coverage.

Clinical effectiveness is context‑dependent and preserved in frail older adults when conservative dosing is used (commonly start 5 mg daily).

Benefit versus risk must be individualised and documented in the chart before initiation.

• DIN: Drug Identification Number (check provincial listings).
• ODB: Ontario Drug Benefit.
• PharmaCare: British Columbia provincial plan.

Indications & Expanded Uses

Patients want to know what amiloride is officially used for and what is off‑label.

Approved Canadian indications align with international practice and include treatment of oedema and adjunctive therapy for hypertension and heart failure, often used alone or combined with thiazide diuretics.

Standard adult starting doses commonly range from 5–10 mg daily, with congestive heart failure titration up to 20 mg/day per product monographs.

Clinically recognised off‑label uses include management of lithium‑induced nephrogenic diabetes insipidus because amiloride blocks ENaC and reduces renal lithium uptake.

Emerging experimental uses — such as inhaled ENaC antagonism for cystic fibrosis or bronchiectasis — remain investigational and are not Health Canada‑approved.

Patient safety requires documenting comorbidities like renal disease and diabetes, and concurrent RAAS therapy before starting amiloride.

Cultural note: in Canada prescribers commonly discuss off‑label rationale explicitly to align with universal‑care expectations and medico‑legal transparency.

Composition & Brand Landscape

Patients asking “what’s in the tablet?” should get a simple answer.

The active ingredient is amiloride hydrochloride (INN: amiloride) and the ATC code is C03DB01.

In Canada generic products predominate and examples include Amiloride and Apo‑Amiloride, supplied as 5 mg tablets in bottles of 100 by Apotex, Sandoz and Teva Canada.

Internationally, the branded product Midamor is known in Australia and various European generics are available under local labels.

Generics are widely available and often preferred on provincial formularies for cost reasons; check Health Canada or provincial DIN lookup for up‑to‑date product identifiers.

• Typical packaging: 5 mg tablets, bottle of 100 in Canada.
• Manufacturers: Apotex, Sandoz, Teva (Canada).

Labels and patient information for Canada‑marketed products are bilingual (English and French) and packaging may carry both languages.

Contraindications & Special Precautions

Worries about whether this drug is safe for a friend with kidney disease are common.

Absolute contraindications include known hypersensitivity to amiloride, anuria, acute or chronic severe renal impairment, Addison’s disease, and high potassium (>5.5 mmol/L) at initiation.

Relative precautions apply to elderly patients, those with diabetes, hepatic dysfunction, and anyone taking ACE inhibitors, ARBs, potassium supplements, or other potassium‑sparing agents.

Canadian high‑risk groups include older adults on polypharmacy, people with CKD (with higher CKD prevalence in some Indigenous communities), and rural patients with limited access to lab testing.

• Absolute Contraindications: hypersensitivity, anuria, severe renal impairment, Addison’s disease, baseline K+ >5.5 mmol/L.
• Relative Precautions: elderly, diabetes, hepatic dysfunction, concurrent RAAS therapy or potassium supplements.

Monitoring Triggers And Practical Monitoring:

Check baseline serum potassium and creatinine before starting.

Repeat labs within 3–7 days and again at 1–2 weeks after initiation or dose change, then monitor periodically; increase frequency if co‑prescribed ACEi/ARB.

Pharmacists in community chains should flag interacting prescriptions at dispensing.

Dosage Guidelines

Patients and prescribers both ask how to start and when to change dose.

Standard adult dosing from product information is to start 5–10 mg once daily, with congestive heart failure dosing ranging from 5–20 mg/day in divided doses and a typical maximum of 20 mg/day.

When used in combination products with thiazides, clinicians typically begin with the 5 mg amiloride component.

Paediatric use is not routine and safety for those under 18 is not established.

Renal impairment is a key determinant: contraindicated in severe impairment or anuria; for mild–moderate impairment use the lowest effective dose and monitor electrolytes closely.

Elderly patients should begin at 5 mg and titrate cautiously while monitoring potassium.

Practical Canadian Note: document baseline labs and monitoring intervals in the medical record and use pharmacy safety screens at dispensing.

Interactions Overview

Many people worry about dangerous drug combinations with diuretics.

Key drug interactions include RAAS inhibitors (ACE inhibitors, ARBs), potassium supplements, potassium‑sparing diuretics and aldosterone antagonists, all of which increase hyperkalemia risk when combined with amiloride.

NSAIDs may blunt diuretic response and worsen renal function, raising the risk of electrolyte disturbances.

Triamterene co‑administration is contraindicated due to additive ENaC blockade and hyperkalemia risk.

• Top Interactions: ACEi/ARB + amiloride — high hyperkalemia risk; avoid or monitor closely.
• Potassium Supplements/Salts: avoid concurrent use unless monitored frequently.
• NSAIDs: monitor renal function when combined.

Advise patients about salt substitutes and potassium‑rich foods and review OTC sports drinks and supplements.

Cultural Perceptions & Patient Habits

Patients often want reassurance about monitoring and access, and community context shapes expectations.

Canadians typically expect clear risk–benefit conversations and bilingual patient materials when relevant.

Community trust in pharmacists is high and many patients consult pharmacists about side effects, interactions and cost.

On public forums and local groups, common patient concerns include hyperkalemia risk, pill burden with polypharmacy and access to regular blood work.

Rural patients report more barriers to timely laboratory testing while Indigenous communities often emphasise culturally safe care and access gaps for CKD and hypertension follow‑up.

• Common Patient Terms: hyperkalemia — high potassium in blood; ENaC — epithelial sodium channel; DIN — drug identification number.
• Clinician Tip: provide plain‑language bilingual handouts and coordinate with provincial home lab services for rural patients.

Availability & Pricing Patterns

Patients ask where to get amiloride and whether insurers will pay.

Amiloride is marketed in Canada as generics — Amiloride and Apo‑Amiloride — commonly in 5 mg tablets, bottle of 100, supplied by Apotex, Sandoz and Teva Canada.

Major pharmacy chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs dispense amiloride when prescribed, and community pharmacies stock generic supplies.

Pricing and public coverage vary by province; some formularies list generic amiloride while others prefer thiazide‑combination products, so check provincial formularies or DIN lookup for coverage details.

Online Canadian pharmacies dispense with prescription verification; cross‑border pricing differences exist but importation is regulated — patients should consult Health Canada guidance.

In our online pharmacy, amiloride is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

• Check ODB, PharmaCare and RAMQ online formularies for provincial coverage details.

Comparable Medicines And Preferences

Deciding which potassium‑sparing agent to use depends on the clinical picture.

Alternatives available in Canada include triamterene (another ENaC agent) and aldosterone antagonists such as spironolactone or eplerenone, plus thiazide and loop diuretics used alone or in combination.

Decision factors include potassium profile, presence of RAAS co‑therapy, cost and specific comorbidities.

For example, amiloride protects potassium levels compared with thiazides but does not provide aldosterone receptor antagonism; spironolactone is preferred post‑MI or in heart failure for mineralocorticoid blockade.

Clinical pearl: if a patient cannot tolerate an aldosterone antagonist, amiloride may be an option for potassium sparing but will not substitute for mineralocorticoid blockade.

FAQ

• Can I take amiloride with an ACE inhibitor? — Co‑prescription raises hyperkalemia risk; clinicians usually monitor potassium closely or avoid the combination if baseline K+ or eGFR are abnormal.
• Are there foods I must avoid? — Avoid excess potassium from salt substitutes and be mindful of very high‑potassium diets; routine fruit and vegetables remain appropriate but discuss diet with the clinician.
• What if I miss a dose? — Take as soon as remembered unless it is close to the next dose; do not double the dose.
• Will my provincial plan cover it? — Coverage varies by province (ODB, PharmaCare, RAMQ); check your provincial formulary or ask a pharmacist for DIN‑specific information.
• Is it safe in pregnancy or breastfeeding? — Use only if benefits outweigh risks; consult obstetric care and document the discussion.

Guidelines For Proper Use (Pharmacist & Provincial Tips)

1. Verify the indication and confirm the prescriber’s intent for potassium‑sparing use or combination therapy.
2. Review the patient’s medication list for ACEi/ARB, potassium supplements, NSAIDs or other potassium‑sparing agents.
3. Obtain baseline serum potassium and creatinine before dispensing.
4. Counsel the patient on signs of hyperkalemia such as muscle weakness, palpitations and sudden fatigue.
5. Recommend a monitoring schedule: baseline, 3–7 days after start or dose change, 1–2 weeks, then monthly until stable and every 3–6 months thereafter as appropriate.
6. Use provincial DIN lookup tools before substitution and follow ODB, PharmaCare and RAMQ rules when submitting for coverage.
7. Store at 20–25°C and protect from moisture; advise patients to keep medication in original container.
8. In overdose with suspected hyperkalemia, refer to urgent care for immediate management.

Encourage bilingual counselling materials and remote or home lab options for rural patients when available.

Delivery Across Canada (English)